MX2016009663A - Derivados de icariina. - Google Patents

Derivados de icariina.

Info

Publication number
MX2016009663A
MX2016009663A MX2016009663A MX2016009663A MX2016009663A MX 2016009663 A MX2016009663 A MX 2016009663A MX 2016009663 A MX2016009663 A MX 2016009663A MX 2016009663 A MX2016009663 A MX 2016009663A MX 2016009663 A MX2016009663 A MX 2016009663A
Authority
MX
Mexico
Prior art keywords
icariin
derivatives
disclosed
icariin derivatives
compounds
Prior art date
Application number
MX2016009663A
Other languages
English (en)
Inventor
Wei Sheng
List Alan
Lawrence Nicholas
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of MX2016009663A publication Critical patent/MX2016009663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones

Abstract

Se describen derivados de icariina. Se describen compuestos de Fórmula I-VIII, tal como se definen en la presente. También se describen métodos para utilizar dichos compuestos para el tratamiento del cáncer y de inflamación.
MX2016009663A 2014-01-23 2015-01-23 Derivados de icariina. MX2016009663A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461930757P 2014-01-23 2014-01-23
US201461977985P 2014-04-10 2014-04-10
PCT/US2015/012749 WO2015112898A1 (en) 2014-01-23 2015-01-23 Icariin derivatives

Publications (1)

Publication Number Publication Date
MX2016009663A true MX2016009663A (es) 2016-11-17

Family

ID=53681995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009663A MX2016009663A (es) 2014-01-23 2015-01-23 Derivados de icariina.

Country Status (8)

Country Link
US (2) US20170044127A1 (es)
EP (2) EP3097088A4 (es)
JP (2) JP2017503833A (es)
AU (2) AU2015209143A1 (es)
BR (1) BR112016016870A8 (es)
CA (1) CA2937905A1 (es)
MX (1) MX2016009663A (es)
WO (1) WO2015112898A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
NZ595747A (en) 2009-03-18 2015-06-26 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
ES2698620T3 (es) * 2013-10-21 2019-02-05 Lunan Pharmaceutical Group Corp Icaritina para uso en la prevención o el tratamiento de la hematocitopenia
US10550186B2 (en) * 2014-12-04 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
JP2019507796A (ja) * 2016-03-11 2019-03-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド イカリイン及びイカリチン誘導体
CN107022526B (zh) * 2017-03-16 2020-11-27 遵义医学院附属医院 一种诱导人羊膜间充质干细胞向神经元样细胞分化的方法
CN108484510B (zh) * 2018-05-18 2020-05-05 东南大学 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用
KR102273061B1 (ko) * 2019-06-05 2021-07-05 한국원자력연구원 향상된 항염 활성을 갖는 플라보노이드 화합물 및 이를 유효성분으로 포함하는 염증 개선용 조성물
GB202101728D0 (en) * 2021-02-08 2021-03-24 Floratek Pharma Ag Compounds and their use treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
US6187779B1 (en) * 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
EP1133317A1 (de) 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
US6479499B1 (en) * 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7034109B2 (en) 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
US20050226943A1 (en) * 2004-04-01 2005-10-13 Xiaoqiang Yan Extract of sophora flavescens flavonoids and uses thereof
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
EP2262366A4 (en) * 2008-04-18 2012-02-22 Shenogen Pharma Group Ltd COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
CN101843629B (zh) * 2010-06-11 2012-03-14 首都医科大学宣武医院 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
EP2726477A4 (en) * 2011-06-29 2015-08-26 Harvard College SMALL MOLECULAR CD38 HEMMER AND USE METHOD THEREFOR
US20130281398A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation

Also Published As

Publication number Publication date
BR112016016870A8 (pt) 2020-06-16
US20170044127A1 (en) 2017-02-16
AU2015209143A1 (en) 2016-08-04
JP2020189857A (ja) 2020-11-26
JP2017503833A (ja) 2017-02-02
CA2937905A1 (en) 2015-07-30
BR112016016870A2 (pt) 2017-08-08
WO2015112898A1 (en) 2015-07-30
EP3097088A4 (en) 2017-10-04
EP3689420A1 (en) 2020-08-05
US20200354331A1 (en) 2020-11-12
AU2019204363A1 (en) 2019-08-01
EP3097088A1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
ZA201704732B (en) Cyclic dinucleotides useful for the treatment of inter alia cancer
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2016009663A (es) Derivados de icariina.
IL261015B (en) History of methylamine as lysyl oxidase inhibitors for cancer treatment
EP3180010A4 (en) Combination therapy for treating cancer
EP3209382A4 (en) Combination immunotherapy approach for treatment of cancer
EP3307240A4 (en) Combination therapy for the treatment of cancer
MX2018010993A (es) Derivados de icariina e icaritina.
EP3359192A4 (en) POLY THERAPY FOR THE TREATMENT OF CANCER
EP3226901A4 (en) Combination therapy for treatment of cancer
EP3193884A4 (en) Combination therapy for treating cancer
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EP3185884A4 (en) Combination therapy for treatment of cancer
PH12017501879A1 (en) Methods for treating cancer
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MX2015013021A (es) 5-bromo-indirrubinas.
EP3548007A4 (en) CANCER TREATMENT METHODS
EP3185910A4 (en) Methods and compositions for the treatment of cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
IL255167A0 (en) Compounds for the treatment of cancer
EP3242681B8 (en) Novel compounds for the treatment of cancer
AU2018297271A1 (en) Englerin derivatives for treatment of cancer